Common Equity: The sum of all common equity items.
Cellectar Biosciences, Inc. (CLRB) had Common Equity of $8.02M for the most recently reported fiscal year, ending 2025-12-31.
| Income Statement Financials | |
-- |
|
$-21.79M |
|
-- |
|
-- |
|
$22.98M |
|
$-22.98M |
|
$1.19M |
|
$-21.79M |
|
$-22.54M |
|
$-21.79M |
|
$-21.79M |
|
$-21.79M |
|
$-22.54M |
|
$-22.98M |
|
$-22.77M |
|
2.61M |
|
2.61M |
|
$-8.35 |
|
$-8.35 |
|
| Balance Sheet Financials | |
$14.04M |
|
$0.55M |
|
$0.94M |
|
$14.98M |
|
$4.75M |
|
-- |
|
$1.69M |
|
$6.44M |
|
|
Common Equity |
$8.02M |
$8.54M |
|
$8.54M |
|
4.24M |
|
| Cash Flow Statement Financials | |
$-23.12M |
|
$-0.01M |
|
$13.03M |
|
$23.29M |
|
$13.20M |
|
$-10.09M |
|
$2.26M |
|
-- |
|
-- |
|
| Fundamental Metrics & Ratios | |
2.96 |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
$-23.12M |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-271.83% |
|
-255.25% |
|
-145.48% |
|
-255.25% |
|
$2.01 |
|
$-8.87 |
|
$-8.86 |
|